Redesign Science

Principal Investigators: David Rooklin, PhD

Redesign Science is a platform biotech company that operates at the interface of physics-based molecular simulation and deep learning, creating generative AI for drug discovery. Their platform technology is deployed to develop first-in-class Protein Interaction Modulators that target validated targets known to drive the progression of multiple oncogenic and inflammatory diseases. The NUVO™ technology platform is a state-of-the-art solution developed by the company, which integrates physics simulation and generative AI to enhance its internal therapeutics pipeline. With this platform the company can perform intricate simulations of biological systems at a molecular level, forecast drug interactions, and swiftly create new compounds with the potential to become innovative therapies. This technology enables the company to expedite drug discovery and development, minimize expenses, and ultimately offer more efficient treatments to patients.